What is Refludan used for? Refludan is indicated for patients who
have had a reaction to heparin that resulted in reduced platelets and associated blood
clots, in order to prevent more clotting complications Who should not
be treated with Refludan? You should not be given Refludan if you are
allergic to this drug or similar drugs.
Special Warnings for Refludan:
Bleeding is the most common complication of Refludan. If you have the following
conditions, your risk of bleeding may be increased:
- Recent puncture of large vessels or organ biopsy
- Abnormality of blood vessels or organs
- Recent "mini-stroke," stroke, brain surgery, or other central nervous
system procedure
- Uncontrolled severe high blood pressure
- Infection of the heart lining (endocarditis)
- Advanced kidney damage
- Tendency to bleed
- Recent major surgery
- Recent major bleeding
General Precautions with Refludan:
- Your doctor will monitor your treatment by using a test that measures the
clotting time of your blood.
- The dosage of Refludan may be decreased if you have liver or kidney disease.
What should I tell my doctor or health care provider?
Because certain other medications can interact with Refludan, and increase the
risk of bleeding, review all medications that you are taking with your health care
provider, including those that you take without a prescription. Other drugs that break up
or dissolve clots, such as (rt-PA) or streptokinase, or drugs that prevent clots such as
Coumadin, warfarin, or aspirin, can increase your risk of bleeding.
What are some possible side effects of Refludan? (This is NOT
a complete list of side effects reported with Refludan. Your health care provider can
discuss with you a more complete list of side effects.)
Bleeding was the most common adverse event reported during testing of the
product. Bleeding can be severe.
Other side effects occurring in at least 2% of the people studied:
- Abnormal liver function
- Allergic skin reactions
For more detailed information about Refludan, ask your health care provider.
|
